The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Investigating PD-L1 expression as a biomarker in anal cancer trials
Dominik Modest, MD, Charité – Universitätsmedizin Berlin, Germany, discusses the challenges of using PD-L1 expression as a biomarker in anal cancer. Although PD-L1 is a potential marker, data from ongoing studies have yet to confirm its utility. In a trial with 308 patients, the potential for subdividing patient groups based on PD-L1 expression leads to small sample sizes, making meaningful correlations difficult. Dr. Modest emphasizes that such findings would likely be hypothesis-generating rather than definitive. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
